Eton Pharmaceuticals, Inc. (ETON) Stock Price & Analysis
Eton Pharmaceuticals, Inc. (ETON) rose 1.94% to USD 30.53 as of June 10, 2026 at 05:13 UTC, according to Nexqual real-time market data.
ETON last closed at USD 29.95; the session ranged USD 29.91–31.11 on volume of 215,981 shares. Market capitalization is $836.29M, with a 52-week range of USD 13.09–35.66 (NGM). Source: Nexqual, June 10, 2026 at 05:13 UTC.
Key Statistics (as of June 10, 2026 at 05:13 UTC)
| Price | USD 30.53 |
|---|---|
| Change | ▲ 1.94% (up) |
| Previous Close | USD 29.95 |
| Open | USD 30.32 |
| Day Range | USD 29.91 – 31.11 |
| 52-Week Range | USD 13.09 – 35.66 |
| Volume | 215,981 shares |
| Market Cap | $836.29M |
| Exchange | NGM |
Technical Analysis (ETON)
Nexqual's technical model rates ETON "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 05:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.4 (neutral) |
| vs SMA50 | Above (USD 27.8) |
| MACD | 0.35 (positive) |
Analyst Ratings (ETON)
Wall Street analysts rate ETON "None" based on 3 analysts, with a mean price target of USD 45.67 (range USD 40–57), per Nexqual as of June 10, 2026 at 05:13 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 45.67 |
| High Target | USD 57 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (ETON)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.19 |
| Revenue Estimate | $26.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.14 vs est 0.14 ▲ beat |
| 2025-12-31 | USD 0.19 vs est 0.2 ▼ miss |
| 2025-09-30 | USD 0.04 vs est 0.16 ▼ miss |
| 2025-06-30 | USD 0.03 vs est 0.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Financials & Fundamentals (ETON)
| Total Revenue | $86.93M |
|---|---|
| Revenue Growth (YoY) | +40.40% |
| Gross Margin | +59.72% |
| Operating Margin | +11.39% |
| Profit Margin | -1.70% |
| ROE | -5.36% |
| Debt / Equity | 102.11 |
| Current Ratio | 1.21 |
| Total Cash | $19.66M |
| Total Debt | $31.26M |
| Free Cash Flow | $2.44M |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Financial Health Score (ETON)
Nexqual rates Eton Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:13 UTC.
| Growth | Strong — Revenue +105% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 11% |
| Balance Sheet | Mixed — $20M cash vs $31M debt |
| Cash Flow | Mixed — FCF $2M, slim 3.1% margin |
| Efficiency | Critical — ROE -5%, ROA 4.8% |
Ownership (ETON)
| Insider Ownership | +4.45% |
|---|---|
| Institutional Ownership | +65.40% |
| Shares Outstanding | 27.39M |
| Float | 21.00M |
| Short % of Float | +6.47% |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Leadership (ETON)
Eton Pharmaceuticals, Inc. is led by Sean E. Brynjelsen (age 53), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:13 UTC.
| President, CEO & Director | Sean E. Brynjelsen (age 53) |
|---|---|
| Chief Financial Officer | Judith M. Matthews (age 55) |
| Executive Vice President of Operations | Danka Radosavljevic |
| Senior Vice President of Sales Operations | Scott Grossenbach |
Major Backers & Investors (ETON)
Notable institutional backers of Eton Pharmaceuticals, Inc. include Opaleye Management Inc., EcoR1 Capital, LLC, Nantahala Capital Management, LLC, according to Nexqual as of June 10, 2026 at 05:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 10.44% |
| EcoR1 Capital, LLC | 7.93% |
| Nantahala Capital Management, LLC | 4.29% |
| National Philanthropic Trust | 1.8% |
| Morgan Stanley | 1.74% |
| Westside Investment Management, Inc. | 1.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.47% |
| Vanguard Group | 7.64% |
| Geode Capital | 2.11% |
| State Street | 1.94% |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
From Eton Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, if we change the manufacturer of a product or our API, the FDA may require stability or other data from the new manufacturer.
- We also rely on our trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary position.
- If we do not comply with applicable requirements, we may be fined, the government may refuse to approve our marketing applications or allow us to manufacture or market our products, and we may be criminally prosecuted.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FENC | Fennec Pharmaceuticals Inc. | USD 8.77 | ▲ 0.8% |
| AQST | Aquestive Therapeutics, Inc. | USD 3.99 | ▲ 1.53% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 6.12 | ▲ 1.32% |
| HYPD | Hyperion DeFi, Inc. | USD 2.59 | ▼ 13.38% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:13 UTC. This page is informational and not investment advice.